Postviral Anti-PF4 Immunothrombosis in Children: A Narrative Review with Practical Guidance
Hämostaseologie · 13.03.2026
DOI: 10.1055/a-2791-8607 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hämostaseologie, erschienen am 13.03.2026. Verfasst von Günalp Uzun und 2 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Clinical and Experimental Transfusion Medicine, University Hospital of Tübingen, Tübingen, Germany. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Deutsche Forschungsgemeinschaft, Deutsche Herzstiftung.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Postviral antiplatelet factor 4 (PF4) immunothrombosis is an emerging pediatric entity characterized by thrombocytopenia, thrombosis, and markedly elevated D-dimer levels and anti-PF4 antibodies. It shares immunopathologic features with vaccine-induced immune thrombotic thrombocytopenia but arises after natural infection, most often adenoviral infection. We reviewed pediatric cases and mechanistic studies identified through PubMed and reference screening (latest search: November 20, 2025), with a focus on pathophysiology, differential diagnosis, laboratory evaluation, and treatment. We identified 10 pediatric patients, with a reported mortality rate of 20%. Children typically presented with acute severe headache, focal neurological deficits, and thrombocytopenia 5–14 days after recent viral illness. All reported cases had markedly increased D-dimers. Rapid immunoassays for heparin-induced thrombocytopenia were often negative; PF4-specific enzyme-linked immunosorbent assay and PF4-enhanced functional assays were positive. Treatments in published cases included anticoagulation (9/10 cases), intravenous immunoglobulin (5/10 cases), and plasma exchange therapy (3/10 cases). On the basis of these findings and mechanistic parallels, we propose a diagnostic and therapeutic approach, acknowledging the limited evidence base. In conclusion, postviral anti-PF4 immunothrombosis in children, although rare, is potentially fatal and likely underrecognized. Further research is needed to establish standardized diagnostic criteria and evidence-based treatment protocols.
Autor:innen und Institutionen
- Institute for Clinical and Experimental Transfusion Medicine, University Hospital of Tübingen, Tübingen, Germany.
- Pediatric Thrombosis and Hemostasis Unit, Pediatric Hemophilia Center, Dr. von Hauner Children's Hospital, LMU Munich, Munich, Germany.
Förderung
- Deutsche Forschungsgemeinschaft
- Deutsche Herzstiftung
Zitieren
APA
Uzun, G., Olivieri, M., & Bakchoul, T. (2026). Postviral Anti-PF4 Immunothrombosis in Children: A Narrative Review with Practical Guidance. Hämostaseologie. https://doi.org/10.1055/a-2791-8607
Vancouver
Uzun G, Olivieri M, Bakchoul T. Postviral Anti-PF4 Immunothrombosis in Children: A Narrative Review with Practical Guidance. Hämostaseologie. 2026. doi:10.1055/a-2791-8607
BibTeX
@article{Uzun2026,
author = {Uzun, Günalp and Olivieri, Martin and Bakchoul, Tamam},
title = {Postviral Anti-PF4 Immunothrombosis in Children: A Narrative Review with Practical Guidance},
journal = {Hämostaseologie},
year = {2026},
doi = {10.1055/a-2791-8607}
}
EUVIMED